Literature DB >> 4033118

The effect of spironolactone on genital skin 5 alpha-reductase activity.

P C Serafini, J Catalino, R A Lobo.   

Abstract

The effect of spironolactone (S) on genital skin 5 alpha-reductase activity (5 alpha-RA) of hirsute women (HW) in vivo as well as in normal genital skin in vitro was evaluated. Thirteen HW (Ferriman-Gallwey score of 23.3 +/- 2.8) received S 100 mg twice a day for a month. Twenty-three non-hirsute women were selected as controls for the assessment of genital skin 5 alpha-RA. S was added to incubations of genital skin from 9 additional controls in vitro in concentrations from 1.2 X 10(-8) to 10(-5) M. HW had significantly higher conversion ratios (CR) of T to DHT compared to controls (P less than 0.05). Post treatment values for the CR T to DHT were significantly lower than prior to S (17.5 +/- 1.7 and 8.05 +/- 1.2%, P less than 0.05) and the mass of DHT produced also decreased by 37 +/- 9% (P less than 0.05). The CR T to 3 alpha-diol decreased by 30 +/- 9% (P less than 0.05). In 11 of 13 women, a significant reduction of 5 alpha-RA was demonstrated while in 2 patients the activity remained unchanged. The maximum in vitro inhibitory effect of S on the CR T to DHT occurred with a concentration of 1.2 X 10(-5) M (P less than 0.01). In conclusion, S has a direct inhibitory effect on 5 alpha-RA. The beneficial effect of S treatment in HW may be related, in part, to this inhibition of 5 alpha-RA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4033118     DOI: 10.1016/0022-4731(85)90236-5

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  7 in total

Review 1.  How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

Authors:  E Diamanti-Kandarakis
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 2.  Hirsutism: evaluation and management.

Authors:  R E Watson; R Bouknight; P C Alguire
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

Review 3.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

4.  Altered balance between the 5 alpha-reductase and aromatase pathways of androgen metabolism during controlled ovarian hyperstimulation with human menopausal gonadotropins.

Authors:  C C Slater; L Chang; F Z Stanczyk; R J Paulson
Journal:  J Assist Reprod Genet       Date:  2001-10       Impact factor: 3.412

Review 5.  A risk-benefit assessment of pharmacological therapies for hirsutism.

Authors:  E Carmina
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver.

Authors:  A Francavilla; A Di Leo; P K Eagon; L Polimeno; F Guglielmi; G Fanizza; M Barone; T E Starzl
Journal:  Gastroenterology       Date:  1987-10       Impact factor: 22.682

7.  Lack of endocrine systemic side effects after topical application of spironolactone in man.

Authors:  F O Rey; C Valterio; L Locatelli; A A Ramelet; J P Felber
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.